Objective: We investigated the short-term and 1-year clinical outcomes of 129 children who received intensive cardiopulmonary support during hematopoietic stem cell transplant. Intensive cardiopulmonary support was defined as receiving at least one of the following interventions: continuous positive pressure ventilation, dopamine infusion greater than or equal to 10 mcg/kg/minute, or the use of any other vasoactive infusion. Duration of intensive cardiopulmonary support, survival to hospital discharge, and predictors of these outcome variables were compared with 387 hematopoietic stem cell transplant patients who did not receive intensive support during the same period. We also report the 1-year survival; presence of chronic graft-versus-host disease; and renal, cardiac, and pulmonary function for all patients. Design: A multicenter retrospective cohort study. Setting: The ICU and hematopoietic stem cell transplant unit of nine pediatric tertiary care centers. Patients: Children undergoing hematopoietic stem cell transplant who required intensive cardiopulmonary support. Interventions: None. Results: Predictors of the need for intensive support included unrelated donor allogeneic transplant, glomerular filtration rate less than 85 mL/minute/1.73 m 2 , and nonmalignant disease as the indication for transplant. The survival to discontinuation of intensive support for all patients was 62% and 58% for patients who received invasive mechanical ventilatory support. The duration of mechanical ventilation was not predictive of survival. Predictors of intensive support mortality included macroscopic bleeding, engraftment, and pediatric logistic organ dysfunction score greater than one in two domains. Survival to hospital discharge was 50% for the intensive support group and 99% for the nonintensive support group. Overall 1-year survival was 40% in the intensive support population and 65% in the nonintensive support group. There were no significant differences in the survival, rates of chronic graft-versus-host disease, creatinine, forced expiratory volume in 1-minute, cardiac shortening fraction, or performance status in intensive and nonintensive support patients who survived to hospital discharge. Conclusion: Intensive cardiopulmonary support plays an important and potentially life-saving role in the care of pediatric stem cell transplant patients. Survivors of intensive support do not have compromised 1-year survival or organ function compared with children who did not receive intensive support. (Pediatr Crit Care Med 2013; 14:261-267) 
C hildren who undergo hematopoietic stem cell transplant (HSCT) commonly require ICU support. Historically, these patients have had dismal outcomes, particularly when invasive mechanical ventilation was required (1) (2) (3) (4) (5) . Reports in recent years have demonstrated improvement in survival to ICU and hospital discharge (6) (7) (8) (9) (10) . However, the ability to generalize the results of these reports is limited as all of the published pediatric data are single-center studies and clinical practices are known to vary among individual institutions (11) . Other limitations of previous studies include a lack of objective inclusion criteria relative to the level of support provided and the majority included patients at any time posttransplant. Additionally, there is a paucity of data regarding the long-term functioning of survivors of ICU support. We attempt to address these issues in this multicenter study of the shortterm and 1-year outcomes of children who received intensive cardiopulmonary support during their initial stem cell transplant admission. We hypothesized that survival to hospital discharge was superior to historic studies and that children who survived intensive support had similar outcomes at 1 year to their counterparts who did not receive intensive support.
MATERIALS AND METHODS
We performed a multicenter retrospective cohort study of children who required intensive cardiopulmonary support during the initial stem cell transplant admission. We included patients aged 0-21 years with transplant admissions between January 1, 2005 and December 31, 2006 at nine tertiary care institutions. Intensive cardiopulmonary support was defined as receiving at least one of the following interventions: continuous positive pressure ventilation (invasive or noninvasive), dopamine infusion greater than or equal to 10 mcg/kg/minute, or the use of any other vasoactive infusion, such as epinephrine, norepinephrine, or milrinone at any dose. The outcomes of patients who received intensive cardiopulmonary support were compared with children transplanted during the same time period who did not receive intensive support to assess potential predictors of the need for intensive support and clinical differences at 1-year post-transplant. Three nonintensive support patients were identified for each patient who received intensive support. The nonintensive support patients were identified consecutively from the start of the calendar year of admission for each intensive support patient identified. If the number of nonintensive support patients was less than three times the number of intensive support patients at a single center, additional controls were identified from an alternate center in the same manner. Clinical data were extracted from the medical records at the individual transplant centers, compiled on data collection forms for review, and entered into a central database.
Data abstracted from the medical record included each of the following: gender, age, underlying disease, donor type, stem cell source, use of a myeloablative conditioning regimen, use of total body irradiation, pretransplant use of supplemental oxygen, pretransplant forced expiratory volume in 1 s (FEV1), and pretransplant glomerular filtration rate (GFR). For analysis, the underlying disease was categorized as 1) hematologic malignancy, 2) nonhematologic malignancy, or 3) nonmalignant disease. A myeloablative regimen was defined as one expected to produce profound, long-lasting pancytopenia and that would be fatal in most circumstances, unless hematopoiesis was restored by stem cell infusion (12) . The pretransplant FEV1 was dichotomized into less than or equal to 80% predicted vs. greater than 80% predicted. Similarly, the pretransplant GFR was dichotomized into less than or equal to 85 mL/minute/1.73 m 2 vs. greater than 85 mL/minute/1.73 m 2 . Each of these variables was assessed for its association with a need for intensive cardiopulmonary support.
Data from the time of the onset of intensive cardiopulmonary support were abstracted. These abstracted data consisted of the following: indication for cardiopulmonary support (respiratory failure, multiple organ dysfunction syndrome [MODS] , neurologic dysfunction, cardiac dysfunction, sepsis, gastrointestinal bleeding, or other indication), existence of acute graft-versus-host disease (GVHD), presence of macroscopic bleeding, presence of a documented infection identified by serologic methods or culture, and severity of illness as measured by the pediatric logistic organ dysfunction (PELOD) score (13) . The indication for support was categorized as MODS when more than one organ system contributed to the need for intensive support. The hematologic domain was not included in the PELOD score assessment. The use, type, and duration of invasive and noninvasive ventilation were recorded as well as the outcome of that support. The outcomes recorded included successful discontinuation of support, transition to invasive ventilation when noninvasive support was first utilized, or death. The use of vasoactive medications and the need for chest compressions were also recorded. In addition, the use of extracorporeal membrane oxygenation (ECMO), dialysis, and/ or continuous veno-venous hemofiltration were documented. The following variables were assessed for potential increased risk of mortality: age, gender, underlying diagnosis, type of transplant, engraftment status, indication for intensive support, presence of infection or macroscopic bleeding, PELOD score, and ventilatory support.
Survival to discontinuation of intensive support and cause of death, when applicable, were recorded. The overall survival to hospital discharge as well as the 1-year overall and diseasefree survival were recorded for all patients. The presence of chronic GVHD at any time before 1 year, the organ system involved, and the use of immunosuppression at 1 year were recorded. The FEV1, cardiac shortening fraction, creatinine, prescription of pulmonary medications, use of supplemental oxygen, and performance score were recorded for all patients from whom data were available prior to and at 1 year following transplant. The Karnofsky performance score was used for patients age equal to or greater than 18 years and the Lansky performance score for patients aged less than 18 years (14, 15) .
Statistical Analysis
Multivariate logistic regression was used to evaluate potential predictors of the requirement for intensive cardiopulmonary support and predictors of mortality. The Wilcoxon's rank sum test with a two-sided α = 0.05 deemed to be statistically significant was used to address potential differences in performance status between the intensive support and nonintensive support groups at 1 year. Two-sample t tests were used to address potential differences in the FEV1, shortening fraction, and creatinine of the two groups at 1 year. The Fisher's exact test was conducted to evaluate differences in the use of home oxygen and pulmonary medications at 1 year and to compare the survival, incidence of GVHD, and relapse rates between the two groups at 1 year. Univariate and multivariate logistic analyses were performed to assess potential predictors of the need for intensive cardiopulmonary support and of death during the intensive support period. When follow-up data were not available either because the testing was not performed or the results were missing, the analysis was performed with the available data and the number of values presented in the table. Data analysis was generated using SAS software, 8 (SAS Institute, Cary, NC). The study was approved by the Institutional Review Board at each of the participating institutions and the need for informed consent was waived.
RESULTS
A total of 129 subjects received intensive cardiopulmonary support during the study period, and their outcomes were compared with those of 387 nonintensive support patients. The characteristics of both groups are presented in Table 1 . The median duration of time from stem cell infusion to onset of intensive support was 21 days (range 3-245 days). The most common indication for intensive support was respiratory failure (73%, confidence interval [CI] 64% to 82%), followed by sepsis (10%, CI 0% to 26%), and neurologic dysfunction (5%, CI 0% to 22%). MODS, diffuse alveolar hemorrhage, cardiac dysfunction, and gastrointestinal bleeding each represented less than 5% of the indications for support.
On multivariate analysis, patients who had a GFR greater than 85 mL/minute/1.73 m 2 (p = 0.001) or a diagnosis of hematologic malignancy (p < 0.0001) had decreased odds of needing intensive support. Patients who had an unrelated donor had 2.1 (CI 1.2-3.6) times the odds of requiring intensive support compared with those who received a related donor transplant (p = 0.0049). No other potential predictors of intensive support need were identified.
At the onset of intensive support, the majority of patients (59%) did not have hematopoietic recovery, acute GVHD was present in 22% of the allogeneic patients, 26% of patients had clinically significant macroscopic bleeding, 44% had a PELOD score greater than 1 in at least two domains, and 40% of patients had at least one documented infection. Of the patients with viral infections, 26% had more than one documented infection at the onset of support (61% virus, 41% bacterial, and 14% fungal). There was no difference in the percentage of infections between patients with an underlying diagnosis of immunodeficiency and those with other diagnoses.
Respiratory Support
Of the 129 intensive support patients, 97% required positive pressure ventilation. Noninvasive ventilation was used for 43% patients (bilevel positive airway pressure 66%, continuous positive airway pressure 16%, venturi mask 7%, heliox 2%, and a combination of noninvasive therapies 7%). Noninvasive ventilation was provided for a median of 2 days (range 0.25-30 days). The majority of patients who received noninvasive ventilatory support (69%) transitioned to invasive ventilation. The remaining patients either died while receiving noninvasive support (7%) or transitioned off positive pressure support (24%). Invasive ventilatory support (conventional ventilation 63%, conventional and high-frequency ventilation 32%, and high-frequency ventilation only 5%) was provided to 83% of patients including those who transitioned to invasive ventilation from noninvasive support. The median duration of invasive ventilation was 7.5 days (range 0.25-80 days). The median duration of mechanical ventilation for survivors was 9 days (range 1-83) and 12 days (range 0.25-106) for nonsurvivors. The length of invasive ventilation was not associated with the odds of survival.
Cardiac and Renal Support
Vasoactive infusions were provided to 51% of intensive support patients with 19% of subjects receiving more than one agent. Medications used included epinephrine (22%), dopamine (21%), milrinone (10%), and other agents (5%). The median duration of hemodynamic support was 5 days (range 0.25-35 days). No patient received ECMO. Less than 2% of patients received chest compressions and none of these patients survived. Renal support with either dialysis or continuous venovenous hemofiltration was provided to 16% of the intensive support population.
Survival to Discontinuation of Intensive Support and Hospital Discharge
The median duration of intensive support was 12 days (range 0.25-116 days). The overall survival to discontinuation of intensive cardiopulmonary support was 62% for all patients requiring any kind of intensive support and 58% for patients who received invasive ventilatory support. Factors present at the onset of support which were associated with survival to discontinuation of intensive support included the lack of engraftment, absence of macroscopic bleeding, and PELOD score no greater than one in two domains (p < 0.05 for all). The median time from stem cell infusion to death while receiving intensive support was 42 days (range 8-253 days). The causes of death were MODS (45%), respiratory failure (21%), neurologic event (8%), infection (6%), cardiac failure (4%), hepatic failure (4%), and other causes (12%). Of the survivors of the initial intensive support period, 33% of patients received at least one additional period of intensive support during the same admission with 58% of these patients dying prior to discharge from the hospital. The survival to hospital discharge was 50% for patients who received intensive cardiopulmonary support and 99% for those who did not receive intensive support. The cause of death in children who died without intensive support was MODS (two patients) or graft failure (one patient). 
Outcomes at 1-Year Post-Transplant
Of the patients who survived to hospital discharge, there was no significant difference in overall or relapse free survival, performance status, FEV1, use of home oxygen, cardiac shortening fraction, or creatinine at 1-year post-transplant between patients who received intensive cardiopulmonary support and those who did not ( Table 2) . There was a greater use of pulmonary medications in patients who received intensive support 
DISCUSSION
To our knowledge, this is the first multicenter study of the clinical outcomes of pediatric patients who required intensive cardiopulmonary support during the HSCT admission. The study was designed to focus only on patients requiring intensive support as the result of acute transplant-related toxicities.
Only patients who received intensive support during the hospitalization in which stem cells were infused were assessedin contrast to most other studies that have reported differences in outcome in the early and later post-transplant periods (9, 16, 17) . Additionally, intensive cardiopulmonary support was clearly defined based on the need for ventilator support and the degree of hemodynamic support to eliminate the inclusion of patients who were cared for in an ICU, but who required less intensive management (e.g., patients monitored following a routine surgical procedure). The use of a uniform definition of intensive support also minimized the effect of differential ICU referral patterns at the participating institutions.
In this report, an unrelated allogeneic donor transplant, a GFR less than or equal to 85 mL/minute/1.73 m 2 , and an underlying nonmalignant disease were found to be risk factors for the need for intensive support. Predictors of the need for ICU care identified in previous studies include allogeneic transplant, male sex, multiorgan dysfunction, acute GVHD, engraftment syndrome, nonmalignant underlying disease, and advanced stage malignant disease (16, 18, 19) . Allogeneic transplant from all donor sources was not found to be an independent predictor in our study, but the finding of unrelated donor transplant as a risk factor suggests that allogenicity, slower immune reconstitution, and/or the increased immunosuppressive GVHD prophylaxis used in some unrelated donor transplants may predispose to toxicity.
We report an overall survival to discontinuation of intensive cardiopulmonary support of 62% in patients who did not receive mechanical ventilation and 58% when invasive mechanical ventilation was required. The overall survival results are similar to those published by other authors since 2000 (7, (18) (19) (20) (21) (22) (23) . The survival for patients who received invasive ventilation is better than all published studies with the exception of the 59% survival rate reported by Kache et al (7) . Both the overall and mechanical ventilation survivals are superior to reports published prior to 2000 (1-3, 24, 25) . Although the severity of the respiratory failure was not assessed, given that the population studied was limited to seriously ill patients requiring ventilatory support, dopamine greater than 10 mcg/minute, and/or other vasoactive infusions, the results of this study support the contention that survival has improved for pediatric HSCT patients requiring cardiopulmonary support over the past decade. Nonmalignant disease has previously been identified as a risk factor for intensive support (16) . This classification includes a diverse group of diagnoses, including immunodeficiencies, nonmalignant hematologic diseases, and metabolic diseases. In this series, half of the children with an underlying immunodeficiency received intensive hemodynamic support and 50% of those children had an infection identified at the onset of support. As 62% of the remainder of the intensive support population had an indentified infection at the start of support, infection does not appear to explain the greater need for intensive care in this subgroup. Children with metabolic diseases represented 10% of all patients studied and 15% of the intensive support group. This population is known to have high transplant-related toxicity and the large number of patients with metabolic diseases may partially explain nonmalignant disease as a risk factor for intensive support (26) (27) (28) .
There was a statistically significant difference in survival to hospital discharge in patients who did not require intensive cardiopulmonary support compared with who required such support. The in-patient mortality rate for patients who did not receive intensive support was less than 1%, suggesting that HSCT and critical care providers are able to identify children requiring intensive cardiopulmonary support in a time frame sufficient to prevent death on the transplant unit.
The overall survival at 1-year following transplant was lower in patients who received intensive support. However, the 1-year survival of patients who received intensive support and survived to hospital discharge did not differ from patients who did not receive intensive support. Additionally, there was no significant difference in the cardiac, pulmonary, or renal function as measured by shortening fraction, FEV1, or creatinine between the two groups at 1 year. However, a potential difference in pulmonary function was noted between the two groups as there was an increased requirement for pulmonary medications at 1 year in survivors of intensive support compared with those who did not require intensive support. There was also a trend toward an increased requirement for home oxygen in these patients as well (p = 0.0634). In addition, there were no significant differences in the rates of GVHD and relapse at 1 year detected. The lack of difference in the rates of GVHD is noteworthy as endothelial damage and inflammation has been proposed as contributing to the development of GVHD and prolonged invasive ventilation is an inflammatory pulmonary insult (29) (30) (31) .
This study is limited by its retrospective nature and the lack of complete 1-year follow-up. Furthermore, the assessments of organ function and differences in function at 1 year are limited, and, thus, some differences may have been missed. However, the multicenter nature of the study and the use of a cohort group should help minimize these limitations. Additionally, the use of such a study design enables us to build on the singlecenter reports previously published and advance our understanding of this high-risk patient population.
CONCLUSIONS
The results of this study support the contention that survival of intensive cardiopulmonary support during the stem cell transplant admission has improved over the past decade and suggest that survivors of intensive support do not have longterm adverse cardiac, pulmonary, or renal sequelae compared with their counterparts who did not require intensive support. Future prospective studies of this patient population are required to confirm our results and to identify other factors which may enable further improvements in survival.
